High prevalence of developmental venous anomaly in adult patients with midline thalamic diffuse gliomas. (May 2021)

• Record Type: Journal Article
• Authors: Zhou, Xingwang; Niu, Xiaodong; Mao, Qing; Liu, Yanhui
• Is Part Of: Journal of clinical neuroscience. Volume 87(2021)
• Page Start: 59
• Page End: 65
• Publication Date: 2021-05
• Subjects: Developmental venous anomaly -- Thalamic glioma -- H3K27M mutation; Brain -- Surgery -- Periodicals; Neurosciences -- Periodicals; Nervous system -- Surgery -- Periodicals; Brain -- surgery -- Periodicals; Neurosurgical Procedures -- Periodicals; Neurosciences -- Periodicals; Electronic journals; 616.8
• DOI: 10.1016/j.jocn.2021.02.014
• Languages: English
• ISSNs: 0967-5868

Abstract

Highlights: The incidence of DVA in thalamic glioma was 18.18%. Some phenotypic coexpression of shared gene may modulate the development of DVA. Markers such as IDH1 were not associated with the development of DVA. Abstract: Objective: This study aimed to assess the prevalence of developmental venous anomaly (DVA) in patients with thalamic glioma. Furthermore, we explored the association between DVA and some important biomarkers, such as IDH1 mutation, and H3K27M mutation. Patients and Methods: Patients who received tumor resection in West China Hospital between August 2009 and October 2017 were enrolled. Propensity score matching was conducted based on a logistic regression model and 1:1 matching for case and control was used to generate a new cohort from patients with meningioma. Chi-square test, t -test, univariate and multivariate analyses were employed to assess the prevalence of DVA in thalamic glioma and meningioma and to identify risk factors associated with DVA. Results: Ninety-nine patients with thalamic glioma were enrolled in the current study (male, n = 54; female, n = 45). The mean age was 42.9 ± 15.3 years old. We identified a higher prevalence of DVA in 99 patients with thalamic glioma when compared with 99 patients with meningioma (18.18% vs . 7.07%), which was slightly lower than the prevalence of DVA in glioma reported in previous studies. Furthermore, the distribution of gender, age, and tumor grade in DVA did not reach statistical significance. Chi-square test, univariate and multivariate analyses showed that IDH1 mutation, ATRX mutation, MGMT promoter methylation, p53 mutation, MMP9, EGFR, and Top II positive expression, TERT mutation, and H3K27M mutation were not associated with the development of DVA in thalamic glioma. Conclusion: A higher prevalence of DVA was found in thalamic glioma compared with meningioma.